The clinical trial investigates the efficacy of semaglutide, a GLP-1 receptor agonist, in patients with Type 2 Diabetes Mellitus (DMT2) and moderate to severe plaque psoriasis. Given the increasing prevalence of both DMT2 and psoriasis, successful outcomes could position semaglutide as a dual-action therapy, enhancing its market potential. The competitive landscape includes other GLP-1 receptor agonists and psoriasis treatments, necessitating a thorough analysis of efficacy and safety profiles to ensure differentiation. The completion of this trial may also support expanded indications for semaglutide, potentially leading to increased market share and revenue streams for the sponsor, University of Banja Luka, and any future commercial partners.